The Federal Commission for the Protection against Health Risks (Cofepris) has issued a favorable opinion for him oral antiviral treatment against SARS-CoV-2 developed by Pfizer.
This could make possible the marketing of the medicine throughout the national territoryoffering a new tool to combat the disease and protect the population, particularly the most vulnerable groups.
“The opinion issued by the Cofepris Committee is, without a doubt, a step forward in the care and protection of the population,” said Dr. Daniel Bustos, Medical Director of Pfizer. “We need all the tools we have at our disposal to reduce the risks of COVID-19, especially in people over 50 years of age and with risk factors, who continue to be the most prone to serious illness and hospitalization.”
Pfizer's oral treatment, which already has approval for emergency use in Mexico, has been shown to be effective in reducing the risk of hospitalization and death in high-risk patients who contract Covid-19. Its administration in pill form makes it an accessible and convenient option for patients, avoiding the need for hospitalization and facilitating outpatient treatment.
Cofepris, after the exhaustive evaluation of the New Molecules Committee, has recognized the potential of the Pfizer treatment to contribute significantly to the control of the pandemic.
It is expected that, in the coming weeks, the Commission will issue its final determination on the health registration of the drug, paving the way for its commercialization in Mexico.
This approval represents a hopeful milestone in the fight against Covid-19. The incorporation of Pfizer's oral treatment to the arsenal of tools available to combat the disease will undoubtedly have a positive impact on public health and the quality of life of thousands of Mexicans.
Pfizer's oral treatment against Covid-19, which combines the drugs nirmatrelvir and ritonavir, It is administered in pill form twice a day for five days. It is indicated for the treatment of adults with mild to moderate Covid-19 who are at high risk of developing serious complications, such as hospitalization or death.
#Cofepris #authorizes #oral #treatment #Covid19 #Pfizer